<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/206268-process-for-preparation-of-candesartan-cilexetil-crystalline-polymorphs by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 05:18:37 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 206268:PROCESS FOR PREPARATION OF CANDESARTAN CILEXETIL CRYSTALLINE POLYMORPHS</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">PROCESS FOR PREPARATION OF CANDESARTAN CILEXETIL CRYSTALLINE POLYMORPHS</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The present invention relates to processes for preparation of candesartan cilexetil crystalline polymorphs. Thus, for example, candesartan cilexetil is added to toluene, the contents are heated to reflux, stirred for 15 minutes at reflux and the resulting crystals are collected at 0 -5aC by filtration to give candesartan cilexetil crystalline form III.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td> <br><br>
The present invention relates to two novel crystalline forms and a novel 1,4-dioxane solvate of candesartan cilexetil, to processes for their preparation and to pharmaceutical compositions containing them.<br>
BACKGROUND OF THE INVENTION Candesartan cilexetil of formula (1):<br><br>
or	2-Ethoxy-1 -[[2'-(1 H-tetrazol-5-yl)[1,1 '-biphenyl]-4-yl]methyl]-1 H-<br>
benzimidazole-7-carboxylic acid, 1-[[(Cyclohexyloxy)carbonyl]oxy]ethyl ester. Candesartan cilexetil is an antihypertensive agent and its therapeutic uses were disclosed in US 5,196,444. US 5,196,444 also disclosed a crystalline form of candesartan cilexetil (C-type crystalline form). Two crystalline forms of candesartan cilexetil, form I and form II, are described in Chem. Pharm. Bull. 47(2), 182-186(1999).<br>
We have discovered a novel 1,4-dioxane solvate of candesartan cilexetil and two novel crystalline forms of candesartan cilexetil. The novel forms have been found to be stable and reproducible.<br>
The object of the present invention is to provide a stable novel 1,4-dioxane solvate of candesartan cilexetil and two stable crystalline forms of candesartan cilexetil, processes for preparing these forms and pharmaceutical compositions containing them.<br>
DETAILED DESCRIPTION OF THE INVENTION<br>
One aspect of the present invention is to provide a novel 1,4-dioxane solvate of candesartan cilexetil (hereinafter referred to as candesartan cilexetil dioxane solvate). Typically the content of 1,4-dioxane in the solvate is 8.8 to 13.0 % w/w. The candesartan cilexetil dioxane solvate is characterized by an x-ray powder diffraction pattern having peaks expressed as 26 at about 6.0, 10.7,<br><br>
16.2, 18.0, 19.7, 20.6, 21.3, 21.7, and 22.3 degrees. Figure 1 shows typical x-ray powder diffraction pattern of candesartan cilexetil dioxane solvate.<br>
Candesartan cilexetil dioxane solvate is prepared by dissolving crystalline form or amorphous form of candesartan cilexetil in 1,4-dioxane and crystallizing at 5°C to15°C, preferably at 5°C to 10°C.<br>
Another aspect of the present invention is to provide a novel crystalline form of candesartan cilexetil (hereinafter referred to as candesartan cilexetil form III, characterized by an x-ray powder diffraction pattern having peaks at about 6.3, 7.3, 8.1, 8.9, 10.1, 14.6, 15.0, 15.8, and 18.8 degree. Figure 2 shows typical x-ray powder diffraction pattern of candesartan cilexetil form III.<br>
The candesartan cilexetil form III is prepared by dissolving candesartan cilexetil in toluene by heating, cooling the solution slowly to 0°C to 5°C, maintaining at 0°C to 5°C for about 1 hour and separating the crystals formed by filtration. The solvent may be heated to dissolve candesartan cilexetil. Candesartan cilexetil used in the process may be any of the crystalline forms except form III, amorphous form or candesartan cilexetil dioxane solvate.<br>
Another aspect of the present invention is to provide a novel crystalline form of candesartan cilexetil (hereinafter referred to as candesartan cilexetil form IV). The candesartan cilexetil form IV is characterized by an x-ray powder diffraction pattern having peaks at about 6.1, 7.1, 11.6, 11.9, 17.9, 19.8 and 21.2 degree. Figure 3 shows typical x-ray powder diffraction pattern of candesartan cilexetil form IV.<br>
The candesartan cilexetil form IV is prepared by mixing candesartan cilexetil, methyl tert-butyl ether and methanol at 50°C 55°C and maintaining at 20°C to 25°C for about 10 hours. Candesartan cilexetil used in the process may be any of the crystalline forms except form IV, amorphous form or candesartan cilexetil dioxane solvate.<br>
Candesartan cilexetil used in the above processes may be obtained by the known methods.<br>
In accordance with the present invention, there is provided a pharmaceutical composition comprising crystalline form III or form IV of candesartan cilexetil and a pharmaceutical^ acceptable carrier.<br><br>
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a x-ray powder diffraction pattern of candesartan cilexetil dioxane solvate.<br>
Figure 2 is a x-ray powder diffraction pattern of candesartan cilexetil form III. Figure 3 is a x-ray powder diffraction pattern of candesartan cilexetil form IV. x-Ray powder diffraction spectrum was measured on a Siemens D5000 x-ray powder diffractometer having a copper-Ka radiation.<br>
The following examples further illustrate the invention.<br>
Example 1 Candesartan cilexetil C-type crystalline form  (5 gm,  obtained by a process described in US 5,196,444) is dissolved in 1,4-dioxane (50 ml) at 25°C. The solution is cooled to 5°C and maintained for 4 hours at about 5°C.   The separated solid is filtered to yield 3 gm candesartan cilexetil dioxane solvate.<br>
Example 2 Candesartan cilexetil C-type crystalline form (5 gm) is added to toluene (25 ml) and heated to reflux. The contents are maintained under reflux for 15 minutes and then cooled slowly to 0°C in 1 hour and maintained at 0°C to 5°C for 1 hour. The separated crystals are collected by filtration to give 3.5 gm candesartan cilexetil form III.<br>
Example 3 Example 1 is repeated using candesartan cilexetil form III instead of candesartan  cilexetil  C-type  crystalline  form  to  give  Candesartan  cilexetil dioxane solvate.<br>
Example 4 The mixture of candesartan cilexetil C-type crystalline form (5 gm), methyl tert-butyl ether (50 ml) is heated to 55°C, methanol (17 ml) is added to the mixture at 55°C and maintained at about this temperature for 1 hour. The contents are cooled to 25°C and maintained at about 25°C for 13 hours. The separated solid is collected by filtration to give 3 gm candesartan cilexetil form IV.<br>
Example 5<br><br>
Example 2 is repeated using candesartan cilexetil form IV instead of candesartan cilexetil C-type crystalline form to give Candesartan cilexetil form III.<br>
Example 6<br>
Example 4 is repeated using candesartan cilexetil dioxane solvate instead of candesartan cilexetil C-type crystalline form to give Candesartan cilexetil form IV.<br><br><br><br><br>
We claim:<br>
1.	A process for the preparation of candesartan cilexetil crystalline polymorphs,<br>
1,4-dioxane solvate, characterized by an x-ray powder diffraction pattern<br>
having peaks expressed as 29 at about 6.0, 10.7, 16.2, 18.0, 19.7, 20.6,<br>
21.3, 21.7, and 22.3 degrees as shown in figure 1; form III, characterized by<br>
an x-ray powder diffraction pattern having peaks expressed as 29 at about<br>
6.3, 7.3, 8.1, 8.9, 10.1, 14.6, 15.0, 15.8, and 18.8 degrees as shown in figure<br>
2; form IV, characterized by an x-ray powder diffraction pattern having peaks<br>
expressed as 29 at about 6.1, 7.1, 11.6, 11.9, 17.9, 19.8 and 21.2 degrees<br>
as shown in figure 3; as herein described comprising the steps of:<br>
a)	suspending or dissolving candesartan cilexetil in a specific organic solvent or a combination of the specific organic solvents selected from the group consisting of 1,4-dioxane, toluene, methyl tert-butyl ether, methanol; and<br>
b)	isolating i) crystalline candesartan cilexetil 1,4-dioxane solvate when 1,4-dioxane is used as the solvent, ii) crystalline polymorph form III when toluene is used as the solvent, and iii) crystalline polymorph form IV when the combination of methyl tert-butyl ether and methanol is used as the solvent.<br>
2.	The process as claimed in claim 1, wherein the process comprising the steps<br>
of:<br>
a)	dissolving candesartan cilexetil in 1,4-dioxane; and<br>
b)	crystallizing candesartan cilexetil as 1,4-dioxane solvate from the solution at 5°C to 15°C.<br><br>
3.	The process as claimed in claim 2, wherein the content of 1,4-dioxane is 8.8 to 13.0% w/w.<br>
4.	The process as claimed in claim 1, wherein the process comprising the steps of:<br><br>
a)	mixing candesartan cilexetil with toluene;<br>
b)	heating to obtain clear solution;<br>
c)	cooling slowly to 0°C to 5°C in about 1 hour;<br>
d)	maintaining at 0°C to 5°C for about 1 hour; and<br>
e)	collecting the separated candesartan cilexetil crystalline form III by filtration.<br><br>
5.   The process as claimed in claim 1, wherein the process comprising the steps of:<br>
a)	heating the mixture of candesartan cilexetil, methyl tert-butyl ether and<br>
methanol to 50°C to 55°C;<br>
b)	cooling to 20°C to 25°C;<br>
c)	maintaining at 20°C to 25°C for about 10 hours; and<br>
d)	collecting the separated candesartan cilexetil  crystalline form  IV by<br>
filtration.<br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc4LWNoZW5wLTIwMDMtYWJzdHJhY3QucGRm" target="_blank" style="word-wrap:break-word;">778-chenp-2003-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc4LWNoZW5wLTIwMDMtY2xhaW1zIGR1cGxpY2F0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">778-chenp-2003-claims duplicate.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc4LWNoZW5wLTIwMDMtY2xhaW1zIG9yaWdpbmFsLnBkZg==" target="_blank" style="word-wrap:break-word;">778-chenp-2003-claims original.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc4LWNoZW5wLTIwMDMtY29ycmVzcG9uZG5lY2Utb3RoZXJzLnBkZg==" target="_blank" style="word-wrap:break-word;">778-chenp-2003-correspondnece-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc4LWNoZW5wLTIwMDMtY29ycmVzcG9uZG5lY2UtcG8ucGRm" target="_blank" style="word-wrap:break-word;">778-chenp-2003-correspondnece-po.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc4LWNoZW5wLTIwMDMtZGVzY3JpcHRpb24oY29tcGxldGUpIGR1cGxpY2F0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">778-chenp-2003-description(complete) duplicate.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc4LWNoZW5wLTIwMDMtZGVzY3JpcHRpb24oY29tcGxldGUpIG9yaWdpbmFsLnBkZg==" target="_blank" style="word-wrap:break-word;">778-chenp-2003-description(complete) original.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc4LWNoZW5wLTIwMDMtZHJhd2luZ3MucGRm" target="_blank" style="word-wrap:break-word;">778-chenp-2003-drawings.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc4LWNoZW5wLTIwMDMtZm9ybSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">778-chenp-2003-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc4LWNoZW5wLTIwMDMtZm9ybSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">778-chenp-2003-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc4LWNoZW5wLTIwMDMtZm9ybSA0LnBkZg==" target="_blank" style="word-wrap:break-word;">778-chenp-2003-form 4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc4LWNoZW5wLTIwMDMtZm9ybSA1LnBkZg==" target="_blank" style="word-wrap:break-word;">778-chenp-2003-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Nzc4LWNoZW5wLTIwMDMtcGN0LnBkZg==" target="_blank" style="word-wrap:break-word;">778-chenp-2003-pct.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="206267-two-part-binding-adhesive-application-in-a-printing-binding-process.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="206269-methyl-propyl-ketone-peroxide-formulations-and-a-process-to-cure-unsaturated-polyester-resin.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>206268</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>778/CHENP/2003</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>26/2007</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>29-Jun-2007</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>23-Apr-2007</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>21-May-2003</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>HETERO DRUGS LIMITED</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>Hetero House, 8-3-166/7/1, Erragadda, Hyderabad 500 018.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>PARTHASARADHI, Reddy, Bandi</td>
											<td>Hetero House, 8-3-166/7/1, Erragadda, Hyderabad 500 018, Andhrapradesh</td>
										</tr>
										<tr>
											<td>2</td>
											<td>RATHNAKAR, Reddy, Kura</td>
											<td>Hetero Drugs Limited (R &amp; D), Plot No. B-80 &amp; 81, A.P.I.E., Balanagar, Hyderabad 500 018, Andhrapradesh</td>
										</tr>
										<tr>
											<td>3</td>
											<td>RAJI, Reddy, Rapolu</td>
											<td>Hetero Drugs Limited (R &amp; D), Plot No. B-80 &amp; 81, A.P.I.E., Balanagar, Hyderabad 500 018, Andhrapradesh</td>
										</tr>
										<tr>
											<td>4</td>
											<td>MURALIDHARA, Reddy, Dasari</td>
											<td>Hetero Drugs Limited (R &amp; D), Plot No. B-80 &amp; 81, A.P.I.E., Balanagar, Hyderabad 500 018, Andhrapradesh</td>
										</tr>
										<tr>
											<td>5</td>
											<td>SUBASH CHANDER, Reddy, Kesireddy</td>
											<td>Hetero Drugs Limited (R &amp; D), Plot No. B-80 &amp; 81, A.P.I.E., Balanagar, Hyderabad 500 018, Andhrapradesh</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K9/20</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/IN2003/000090</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2003-03-27</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td></td>
									<td></td>
								    <td>NA</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/206268-process-for-preparation-of-candesartan-cilexetil-crystalline-polymorphs by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 05:18:38 GMT -->
</html>
